Industry

Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype Approval based on SWIFT trials showing significantly lower rate of annualized asthma exacerbations in patients receiving depemokimab versus placebo SWIFT data included reduction in exacerbations requiring hospitalization and/or emergency department visits with depemokimab An … [Read more…]

New publication demonstrates that insitro’s POSH platform — integrating pooled CRISPR screening and self-supervised deep learning — successfully breaks the historic compromise between scale and depth to more rapidly identify novel therapeutic targets SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–insitro, the AI therapeutics company built on causal biology, today announced the publication of research in Nature Communications … [Read more…]

MIAMI–(BUSINESS WIRE)–Cardone Ventures, backed by billionaire investor, Grant Cardone and his business partners Brandon and Natalie Dawson, today announced that it has submitted an unsolicited, non-binding proposal to acquire PetMed Express, Inc. (Nasdaq: PETS) (“PetMeds”) for $4.25 per share in cash, representing an implied equity value of approximately $89 million. The proposal was delivered to … [Read more…]

ARLINGTON, Va.–(BUSINESS WIRE)–Recognizing that research facilities use five to 10 times as much energy as office buildings, the International Institute for Sustainable Laboratories (I2SL) has launched the first laboratory-specific software service for creating automated energy audits. The Actionable Insights and Measures (AIM) software allows lab owners, facility managers, engineers, and consultants around the world to … [Read more…]

BOSTON & SHANGHAI–(BUSINESS WIRE)–Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that the first patient has been enrolled in MOSAIC, the company’s Phase 2a clinical trial evaluating ECC4703, ECC0509 and their combination in adults with MRI-based or clinically defined metabolic dysfunction-associated steatohepatitis (MASH). The … [Read more…]

LONDON & SAN FRANCISCO–(BUSINESS WIRE)–Today, Latent Labs announces Latent-X2, a frontier AI model that can design drug-like biologics without iteration. Drug hunters can use Latent Lab’s AI platform, built on Latent-X2, to access difficult targets and accelerate development timelines by reducing wet lab work. The generated designs display drug-like properties including low ex vivo immunogenicity, … [Read more…]

Execution of a 15-year contract including an option to renew with UK Nuclear Decommissioning Authority for access to up to 400 tonnes of reprocessed uranium (RepU), with the potential to deliver tens of thousands of doses of 212Pb every year Partnership with the United Kingdom National Nuclear Laboratory (UKNNL) to scale up the extraction of … [Read more…]

Verified for compliance with European and U.S. regulatory and assessment frameworks, aiming to help reduce traffic accidents caused by drunk driving TOKYO–(BUSINESS WIRE)–Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has developed a technology that accurately detects intoxication levels indicated by driver distraction and drowsiness, and provides driver alerts and vehicle-control interventions as needed … [Read more…]

The Health Care Authority (HCA) and Department of Health (DOH) are equipping health care providers and emergency medical services (EMS) personnel with practical, research-based resources to expand treatment access and reduce overdose deaths. OLYMPIA, Wash.–(BUSINESS WIRE)–The Washington State Health Care Authority (HCA) and Department of Health (DOH) just released a new resource library to help … [Read more…]

John Johnson, current board member, appointed to chairman of the board Michael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of development Commercial launch progresses as RAMP 301 Phase 3 confirmatory trial in recurrent LGSOC completes additional patient enrollment; topline data anticipated in mid-2027 BOSTON–(BUSINESS WIRE)–Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed … [Read more…]